Search Results 181-190 of 15391 for TNF

  1. David A. Wetter, M.D. - Mayo Clinic Faculty Profiles

    Paradoxical autoimmune side effects of tumor necrosis factor-alpha inhibitors, including psoriasis, lupus and vasculitis. Significance to patient care. Dr ...

  2. A Study to Evaluate Safety and Effectiveness of SHP647 as Induction Therapy in Participants with Moderate-to- Severe Crohn's Disease - Mayo Clinic

    ... TNF. Subjects who have had an inadequate response to sulfasalazine or mesalamine should have also failed at least 1 other conventional treatment such as ...

  3. A Study to Evaluate TAK-018 for Prevention of the Recurrence of Postoperative Crohn's Disease (CD) - Mayo Clinic

    This includes anti-tumor necrosis factor-alpha (TNF-α) and anti-integrin therapy, anti- interleukin (IL) 12/23, thiopurines and other immunomodulators ...

  4. Endoscopy Clinical Trials - Mayo Clinic Research

    ... Tumor Necrosis Factor (TNF) therapy. A Study to Evaluate the Natural History of Barrett's Esophagus Using Tethered Capsule Endomicroscopy Jacksonville, FL.

  5. Treatment of Proteinuria Due to Treatment Resistant or Treatment Intolerant Idiopathic FSGS - Mayo Clinic

    ... Tumor Necrosis Factor-Alpha Therapy (anti-TNF α) agent. -Effective contraception from screening, and for 36 weeks after the last dose of investigational ...

  6. Multicenter Study Evaluating Certolizumab Pegol Compared to Placebo in Subjects With axSpA Without X-ray Evidence of AS - Mayo Clinic

    Exposure to more than 1 TNF-antagonist or primary failure to TNF antagonist therapy; History of or current chronic or recurrent infections; Subjects with ...

  7. Study of Canakinumab in Patients With Myelofibrosis - Mayo Clinic

    - Women who are pregnant or breastfeeding. - Patients undergoing concurrent treatment with agents targeting tumor necrosis factor alpha (TNF?) or IL-1 ...

  8. Oatd-01, an Oral Inhibitor of Chitinase-1 (CHIT1), for the Treatment of Active Pulmonary Sarcoidosis - Mayo Clinic

    immunosuppressants or anti-Tumor Necrosis Factor (TNF) agents (or other anti-inflammatory/anti-fibrotic treatment) received not later than 4 months prior to ...

  9. Treatment of Moderate to Severe Refractory Crohn's Disease - Mayo Clinic

    * TNF-alpha inhibitors * IL-12/23 inhibitors * Anti-integrins * JAK inhibitors * OR * Non-response (primary failure), complete loss of response (secondary ...

  10. An Extension Study Monitoring the Safety of Patients with Crohn's Disease Previously Enrolled in the Etrolizumab Phase III Study GA29144 - Mayo Clinic

    Use of TNF antagonists;; Use of antagonists of IL-12 ± IL-23 (e.g., ustekinumab);; Immunization with a live/attenuated vaccine;; Use of anti-adhesion molecules ...